Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria - PubMed

Objective: To determine the prevalence of elevated total and free T, and DHEAS, alone and in combination, in patients with polycystic ovary syndrome (PCOS).

Design: Cross-sectional analysis.

Setting: Tertiary care academic medical center.

Patient(s): Seven hundred twenty patients diagnosed with PCOS according to the National Institutes of Health 1990 criteria.

Intervention(s): History, physical examination, and blood sampling.

Main outcome measure(s): Hyperandrogenemia, defined as at least one androgen value above the 95th percentile of 98 healthy control women (i.e., total T >88 ng/dL, free T >0.75 ng/dL, and DHEAS >2,750 ng/mL).

Result(s): A total of 716 subjects with PCOS were included. The overall prevalence of hyperandrogenemia in PCOS was 75.3%. Supranormal levels of free T were present in 57.6%, of total T in 33.0%, and of DHEAS in 32.7% of patients with PCOS. When assessing the prevalence of two abnormal values, the prevalence of simultaneously elevated androgens was lowest with total T and DHEAS (1.7%) and highest with total T and free T (20.4%). Altogether, simultaneous elevations in all three markers were found in 8.7% of subjects with PCOS.

Conclusion(s): Approximately three-fourths of patients with PCOS diagnosed by the National Institutes of Health 1990 criteria have evidence of hyperandrogenemia; the single most predictive assay was the measurement of free T with approximately 60% of patients demonstrating supranormal levels.

1. 1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–3082. - PubMed
2. 1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: a hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011. - PubMed
3. 1. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrin Metab. 2000;85:2434–2438. - PubMed
4. 1. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephans KC, Taylor K, Boots LR. Androgen excess in Women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metabol. 2004;89:453–462. - PubMed
5. 1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 1992. pp. 377–384.

• R01-HD29364/HD/NICHD NIH HHS/United States
• R01 HD029364-13/HD/NICHD NIH HHS/United States
• R01 HD029364/HD/NICHD NIH HHS/United States
• K24-HD01346-01/HD/NICHD NIH HHS/United States
• K24 HD001346/HD/NICHD NIH HHS/United States